Targeted drug delivery to mammalian mitochondria in living cells

Expert Opinion on Drug Delivery

Volumn 2, Issue 1, 2005, Pages 89-102

  Weissig, Volkmar ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Delocalised cations; Drug targeting; Gene therapy; Intracellular drug delivery; Mitochondria; Mitochondrial diseases; Mitochondrial medicine; Mitochondrial transfection vector; Mitochondriotropic molecules

Indexed keywords

1,1' BIS(2 ETHYL 1,3 DIOXOLAN 2 YL)CRYPTOCYANINE; ANTISENSE OLIGONUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYFLUORESCEIN; CYANINE DYE; CYCLOPHILIN; CYCLOSPORIN A; DEQUALINIUM; DEXTRAN DERIVATIVE; DICHLOROACETIC ACID; DRUG CARRIER; DYNEIN ADENOSINE TRIPHOSPHATASE; FICOLL; HYPOGLYCINE A; LIPOSOME; METHYLTRIPHENYLPHOSPHONIUM; MILDRONATE; MITOCHONDRIAL PROTEIN; PACLITAXEL; PEPTIDE DERIVATIVE; PEPTIDE NUCLEIC ACID; PERHEXILINE; PHOSPHOLIPID; PLASMID DNA; POLYMER; RANOLAZINE; RHODAMINE 123; RIBOZYME; TRIMETAZIDINE; UNINDEXED DRUG;

ANIMAL CELL; CANCER; CELL BASED GENE THERAPY; CELL REGENERATION; CELLULAR DISTRIBUTION; COLLOID; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; GENE DELIVERY SYSTEM; GENE TARGETING; ISCHEMIA; LIPOPHILICITY; MAMMAL CELL; MEDICAL RESEARCH; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NEUROMUSCULAR DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPERFUSION INJURY; REVIEW;

ANIMALS; DNA; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 12344302096     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.1.89     Document Type: Review

References (102)

1. LARSSON N-G, LUFT R: Revolution in mitochondrial medicine. FEBS Lett. (1999) 455:199-202.
2. SCHON EA, DIMAURO S: Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr. Med. Chem. (2003) 10 1241-1253.
3. MURPHY MP, SMITH RA: Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev. (2000) 41 235-250.
4. MANELLA CA: Our changing views of mitochondria. J. Bioenerg. Biomembr. (2000) 32:1-4.
5. PERKINS GA, FREY TG: Recent structural insight into mitochondria gained by microscopy. Micron (2000) 31:97-111.
6. SCHEFFLER IE: Mitochondria make a come back. Adv. Drug Deliv. Rev. (2001) 49:3-26.
7. WEISSIG V, BODDAPATI SV, D'SOUZA GGM, CHENG SM: Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria. Drug Design Reviews - Online (2004) 1:15-28.
8. MORISAKI T, KATANO M: Mitochondria-targeting therapeutic strategies for overcoming chemoresistance and progression of cancer. Curr. Med. Chem. (2003) 10:2517-2521.
9. KOTAKE Y. OHTA S: MPP+ analogs acting on mitochondria and inducing neuro-degeneration. Curr. Med. Chem. (2003) 10 2507-2516.
10. KROEMER G: The mitochondrial permeability transition pore complex as a pharmacological target. An introduction. Curr. Med. Chem. (2003) 10:1469-1472.
11. MALISAN F, TESTI R: Mitochondrial lipids as apoptosis regulators. Curr. Med. Chem. (2003) 10:1573-1580.
12. GALIEGUE S, TINEL N, CASELLAS P: The peripheral benzodiazepine receptor: a promising therapeutic drug target. Curr. Med. Chem. (2003) 10:1563-1572.
13. O'NEILL JW, HOCKENBERY DM: Bcl-2-related proteins as drug targets. Curr. Med. Chem. (2003) 10:1553-1562.
14. PASTORINO JG, HOEK JB: Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr. Med. Chem. (2003) 10:1535-1551.
15. GRANVILLE DJ, GOTTLIEB RA: The mitochondrial voltage-dependent anion channel (VDAC) as a therapeutic target for initiating cell death. Curr. Med. Chem. (2003) 10:1527-1533.
16. HALESTRAP AP, BRENNERB C: The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr. Med. Chem. 2003; 10:1507-1525.
17. WALDMEIER PC, ZIMMERMANN K, QIAN T, TINTELNOT-BLOMLEY M, LEMASTERS JJ: Cyclophilin D as a drug target. Curr. Med. Chem. (2003) 10:1485-1506.
18. CROMPTON M: On the involvement of mitochondrial intermembrane junctional complexes in apoptosis. Curr. Med. Chem. (2003) 10 1473-1484.
19. SORDET O, KHAN QA, KOHN KW, POMMIER Y: Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Canc. Agents (2003) 3:271-290.
20. KROEMER G: Mitochondrial control of apoptosis: an overview. In: Mitochondria and Cell Death. Brown GC, Nicholls DG, Cooper CE (Eds.). Princton University Press: Princton, NJ (1999):1-15.
21. JAMES AM, SMITH RA, MURPHY MP: Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. Arch. Biochem. Biophys. (2004) 423:47-56.
22. GREEN K, BRAND MD, MURPHY MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes (2004) 53(Suppl. 1):S110-S118.
23. COULTER CV, KELSO GF, LIN TK, SMITH RA, MURPHY MP: Mitochondrially targeted antioxidants and thiol reagents. Free Radic. Biol. Med. (2000) 28:1547-1554.
24. FRIDOVICH I: Mitochondria: are they the seat of senescence? Aging Cell (2004) 3:13-16.
25. SZEWCZYK A, WOJTCZAK L: Mitochondria as a pharmacological target. Pharmacol. Rev. (2002) 54:101-127.
26. SMITH RA, PORTEOUS CM, COULTER CV, MURPHY MP: Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem. (1999) 263:709-716.
27. DIMAURO S, SCHON EA: Mitochondrial DNA mutations in human disease. Am. J. Med. Genet. (2001) 106:18-26.
28. WALLACE DC: Diseases of the mitochondrial DNA. Ann. Rev. Biochem. (1992) 61:1175-1212.
29. WALLACE DC: A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found. Symp. (2001) 235 247-263.
30. PULKES T, HANNA MG: Human mitochondrial DNA diseases. Adv. Drug Deliv. Rev. (2001) 49:27-43.
31. MANFREDI G, BEAL MF: The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol. (2000) 10:462-472.
32. D'SOUZA GGM, WEISSIG V: Approaches to mitochondrial gene therapy. Curr. Gene Ther. (2004) 4:317-328.
33. 2+ cycling. Exp. Physiol. (2003) 88:91-97.
34. WATTS JA, KLINE JA: Bench to bedside: the role of mitochondrial medicine in the pathogenesis and treatment of cellular injury. Acad. Emerg. Med. (2003) 10:985-997.
35. RIZZUTO R, BERNARDI P, POZZAN T: Mitochondria as all-round players of the calcium game. J. Physiol. (2000) 529 (Pt 1):37-47.
36. BERNARDI P: Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol. Rev. (1999) 79 1127-1155.
37. KIRICHOK Y, KRAPIVlNSKY G, CLAPHAM DE: The mitochondrial calcium uniporter is a highly selective ion channel. Nature (2004) 427:360-364.
38. RUPP H, ZARAIN-HERZBERG A, MAISCH B: The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz (2002) 27:621-636.
39. DUVVURI M, FENG W, MATHIS A, KRISE JP: A cell fractionation approach for the quantitative analysis of subcellular drug disposition. Pharm. Res. (2004) 21:26-32.
40. LUKACS GL, HAGGIE P, SEKSEK O, LECHARDEUR D, FREEDMAN N, VERKMAN AS: Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. (2000) 275:1625-1629.
41. SEKSEK O, BIWERSI J, VERKMAN AS: Translational diffusion of macromolecule-sized solutes in cytoplasm and nucleus. J. Cell Biol. (1997) 138:131-142.
42. FUSHIMI K, VERKMAN AS: Low viscosity in the aqueous domain of cell cytoplasm measured by picosecond polarization microfluorimetry. J. Cell Biol. (1991) 112:719-725.
43. SODEIK B, EBERSOLD MW. HELENIUS A: Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J. Cell Biol. (1997) 136:1007-1021.
44. KAO HP, ABNEY JR, VERKMAN AS: Determinants of the translational mobility of a small solute in cell cytoplasm. J. Cell Biol. (1993) 120:175-184.
45. LEDLEY FD: Pharmaceutical approach to somatic gene therapy. Pharm. Res. (1996) 13:1595-1614.
46. HOROBIN RW: Biological staining: mechanisms and theory. Biotech. Histochem. (2002) 77:3-13.
47. HOROBIN RW: Uptake, distribution and accumulation of dyes and fluorescent probes within living cells: a structure-activity modelling approach. Adv. Colour Sci. Technol. (2001) 4:101-107.
48. WOODFIELD K, RUCK A, BRDICZKA D, HALESTRAP AP: Direct demonstration of a specific interaction between cyclophilin D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem. J. (1998) 336:287-290.
49. WEISSIG V, CHENG SM, D'SOUZA G: Mitochondrial pharmaceutics. Mitochondrion (2004) 3:229-244.
50. SRERE PA: The infrastructure of the mitochondrial matrix. Trends Biochem. Sci. (1980) 5:120-121.
51. GOODSELL DS: Inside a living cell. Trends Biochem. Sci. (1991) 16:203-206.
52. WEISSIG V: Mitochondrial-targeted drug and DNA delivery. Crit. Rev. Ther. Drug Carrier Syst. (2003) 20:1-62.
53. PARTIKIAN A, OLVECZKY B, SWAMINATHAN R, LI Y, VERKMAN AS: Rapid diffusion of green fluorescent protein in the mitochondrial matrix. J. Cell Biol. (1998) 140:821-829.
54. MURPHY MP: Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. (1997) 15:326-330.
55. MURATKOVSKA A, LIGHTOWLERS RN, TAYLOR RW, WILCE JA, MURPHY MP: Targeting large molecules to mitochondria. Adv. Drug Deliv. Rev. (2001) 49:189-198.
56. PAUNESKU T, VOGT S, MASER J et al.: Development of nanocomposites with mitochondrial specifity (Abstract). Mitochondrion 2004) 4:75-76.
57. MURPHY MP: Slip and leak in mitochondrial oxidative phosphorylation. Biochim. Biophys. Acta (1989) 977:123-141.
58. KOEHLER CM: Protein translocation pathways of the mitochondrion. FEBS Lett. (2000) 476:27-31.
59. LITHGOW T: Targeting of proteins to mitochondria. FEBS Lett. (2000) 476:22-26.
60. CHINNERY PF, TAYLOR RW, DIEKERT K, LILL R, TURNBULL DM, LIGHTOWLERS RN: Peptide nucleic acid delivery to human mitochondria. Gene Ther. (1999) 6:1919-1928.
61. FLIERL A, JACKSON C, COTTRELL B, MURDOCK D, SEIBEL P, WALLACE DC: Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid. Mol. Ther. (2003) 7 550-557.
62. GEROMEL V, CAO A, BRIANE D: Mitochondria transfection by oligonucleotides containing a signal peptide and vectorized by cationic liposomes. Antisense Nucleic Acid Drug Dev. (2001) 11 175-180.
63. MIHARA K, OMURA T: Cytoplasmic chaperones in precursor targeting to mitochondria: the role of MSF and hsp 70. Trends Cell Biol. (1996) 6:104-108.
64. MIHARA K, OMURA T: Cytosolic factors in mitochondrial protein import. Experientia (1996) 52:1063-1068.
65. DEL GAIZO V, PAYNE RM: A novel TAT-Mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther. (2003) 7:720-730.
66. DEL GAZIO V, MACKENZIE JA, PAYNE RM: Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. (2003) 80:170-180.
67. ROSS MF, FILIPOVSKA A, SMITH RA, GAIT MJ, MURPHY MP: Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem. J. (2004).
68. CHEN LB, SUMMERHAYES IC, JOHNSON LV, WALSH, ML, BERNAL, SD, LAMPIDIS TJ: Probing mitochondria in living cells with rhodamine 123. Cold Spring Harb. Symp. Quant. Biol. (1982) 46:141-155.
69. LIBERMAN EA, TOPALY VP, TSOFINA LM, JASAITIS AA, SKULACHEV VP: Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature (1969) 222:1076-1078.
70. WEISS MJ, WONG JR, HA CS: Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc. Natl. Acad. Sci. USA (1987) 84 5444-5448.
71. OSEROFF AR, OHUOA D, ARA G, MCAULIFFE D, FOLEY J, CINCOTTA L: Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells. Proc. Natl. Acad. Sci. USA (1986) 83 9729-9733.
72. MORGAN J, WHITAKER JE, OSEROFF AR: GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targeting dye victoria blue BO. Photochem. Photobiol. (1998) 67 155-164.
73. MURPHY MP: Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction. Expert Opin. Biol. Ther. (2001) 1:753-764.
74. JAMES AM, BLAIKIE FH, SMITH RA, LIGHTOWLERS RN, SMITH PM, MURPHY MP: Specific targeting of a DNA-alkylating reagent to mitochondria. Synthesis and characterization of [4-((11aS -7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiaze pin-5-on-8-oxy)butyl]-triphenylphosphonium iodide. Eur. J. Biochem. (2003) 270:2827-2836.
75. KELSO GF, PORTEOUS CM, COULTER CV, SMITH RA, MURPHY MP: Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. (2001) 276:4588-4596.
76. BURNS RJ, SMITH RA, MURPHY MP: Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix. Arch. Biochem. Biophys. (1995) 322 60-68.
77. MURATOVSKA A, LIGHTOWLERS RN, TAYLOR RW, SMITH RA, MURPHY MP: Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res. (2001) 29:1852-1863.
78. SMITH RA, PORTEOUS CM, GANE AM, MURPHY MP: Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA (2003) 100: 5407-5412.
79. D'SOUZA GG, RAMMOHAN R, CHENG SM, TORCHILIN VP, WEISSIG V: DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J. Control. Release (2003) 92:189-197.
80. WEISSIG V, LIZANO C, TORCHILIN VP: Selective DNA release from DQAsome/ DNA complexes at mitochondria-like membranes. Drug Deliv. (2000) 7:1-5.
81. WEISSIG V, D'SOUZA GG, TORCHILIN VP: DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J. Control. Release (2001) 75:401-408.
82. WEISSIG V, LIZANO C, GANELLIN CR, TORCHILIN VP: DNA binding cationic bolasomes with delocalized charge center: a structure-activity relationship study. S.T.P. Pharma Sciences (2001) 11:91-96.
83. WEISSIG V, LASCH J, ERDOS G, MEYER HW, ROWE TC, HUGHES J: DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm. Res. (1998) 15:334-337.
84. WEISSIG V, MOGEL HJ, WAHAB M, LASCJ J: Computer simulations of DQAsomes Intl. Symp. Control. Rel. Bioact Mater. Controlled Release Society, Las Vegas, Nevada, USA (1998):312.
85. LASCH J, MEYE A, TAUBERT H, KOELSCH R, MANSA-ARD J, WEISSIG V: Dequalinium vesicles form stable complexes with plasmid DNA which are protected from DNase attack. Biol. Chem. (1999) 380:647-652.
86. WEISSIG V, TORCHILIN VP: Towards mitochondrial gene therapy: DQAsomes as a strategy. J. Drug Target. (2001) 9:1-13.
87. WEISSIG V, TORCHILIN VP: Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv. Drug Deliv. Rev. (2001) 49:127-149.
88. WEISSIG V, CHENG SM, D'SOUZA GG, TORCHILIN VP, SCHUBERT R, KIMPFLER A: Towards mitochondria-specific delivery of apoptosis-inducing agents: DQAsomal incorporated paclitaxel Intl. Symp. Control. Rel. Bioact. Mater. Controlled Release Society. Glasgow, Scotland (2003).
89. EISENHAUER EA, VERMORKEN JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 55 5-30.
90. ANDRE N, CARRE M, BRASSEUR G: Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. (2002) 532:256-260.
91. SELIGSON AL, TERRY RC, BRESSI JC, DOUGLASS JG 3rd, SOVAK M: A new prodrug of paclitaxel: synthesis of Protaxel. Anti-Cancer Drugs (2001) 12:305-313.
92. CHEN LB: Mitochondrial membrane potential in living cells. Ann. Rev. Cell Biol. (1988) 4:155-181.
93. MODICA-NAPOLITANO JS, APRILLE JR: Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. (2001) 49:63-70.
94. MODICA-NAPOLITANO JS, APRILLE JR: Basis for the selective cytotoxicity of rhodamine 123. Cancer Res. (1987) 47 4361-4365.
95. KLIBANOV AL, MARUYAMA K, TORCHILIN VP, HUANG L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. (1990) 268:235-237.
96. LASCH J, WEISSIG V, BRANDL M: Preparation of liposomes. In: Liposomes - A Practical Approach. Torchilin VP, Weissig V (Eds). Oxford University Press, Oxford (2003):3-30.
97. TORCHILIN VP, WEISSIG V, MARTIN FJ, HEATH TD, NEW RRC: Surface modification of liposomes. In: Liposomes - A Practical Approach. Torchilin VP, Weissig, V, (Eds). Oxford University press, Oxford (2003):193-230.
98. SCHWARZE SR, HO A, VOCERO-AKBANI A, DOWDY SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 285:1569-1572.
99. TREHIN R, MERKLE HP: Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur. J. Pharm. Biopharm. (2004) 58:209-223.
100. SNYDER EL, DOWDY SF: Cell penetrating peptides in drug delivery. Pharm. Res. (2004) 21:389-393.
101. JARVER P, LANGEL U: The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov. Today (2004) 9 395-402.
102. TORCHILIN VP, LEVCHENKO TS: TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci. (2003) 4 133-140.